Wendy Wilson
Family · Beckley, WVNPI 1386068690
Payments from drug & device makers
Across 368 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$835
- Lilly USA, LLC$714
- Bayer$453
- AstraZeneca$426
- Abbott$365
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,037 |
| Novo Nordisk | 54 | $835 |
| Lilly USA, LLC | 42 | $714 |
| Bayer | 14 | $453 |
| AstraZeneca | 21 | $426 |
| Abbott | 18 | $365 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $339 |
| Shield Therapeutics Inc | 11 | $291 |
| Boehringer Ingelheim | 16 | $280 |
| Amgen | 14 | $206 |
| Esperion Therapeutics, Inc. | 16 | $196 |
| Phathom Pharmaceuticals, Inc. | 4 | $143 |
| Johnson & Johnson | 3 | $129 |
| Novartis | 6 | $121 |
| GSK | 6 | $86 |
| Pfizer | 4 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $69 |
| Merck | 4 | $69 |
| Lundbeck LLC | 1 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Exact Sciences | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Organon | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $12 |
How this compares
$6,402 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $66,769 |
| OzempicSemaglutide | 27 | $42,444 |
| LinzessLinaclotide | 42 | $41,781 |
| MounjaroTirzepatide | 30 | $31,219 |
| JardianceEmpagliflozin | 26 | $26,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $26,408 |
| GemtesaVibegron | 14 | $16,786 |
| FarxigaDapagliflozin Propanediol | 16 | $16,697 |
| TrulicityDulaglutide | 11 | $11,952 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,848 |
| Dexlansoprazole DrDexlansoprazole | 14 | $5,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $3,810 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,073 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $3,010 |
| SynthroidLevothyroxine Sodium | 27 | $2,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $66,76968 claims |
| AbbVieLinzess, Synthroid | $1,037 | $44,40469 claims |
| Lilly USA, LLCMounjaro, Trulicity | $714 | $43,17141 claims |
| Novo NordiskOzempic | $835 | $42,44427 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $86 | $32,25653 claims |
| Boehringer IngelheimJardiance | $280 | $26,92126 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $41 | $16,78614 claims |
| AstraZenecaFarxiga | $426 | $16,69716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.
Other family in Beckley
- Erica ShrewsburyBeckley$20K
- Melissa RamseyBeckley$12K
- Jeanine RobinsonBeckley$10K
- Dana FrobleBeckley$10K
- Rosalind BerryBeckley$9K
- Leslie LillyBeckley$8K
- Jennifer WhaleyBeckley$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.